NRIX Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-clas

NRIX RHHBY (more) Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-class btk degrader bexobrutideg across malignant hematology, immunology and neurology Nurix Therapeutics - to receive $700M upfront, up to $2.30B in total potential payments - Development costs shared 40% Nurix, 60% Roche; U.S. profits and losses split equally - Roche to Co-commercialize bexobrutideg in U.S.; Roche commercializes ex-U.S.; Nurix to receive royalties - Co and Roche to jointly advance bexobrutideg in cll, B-cell malignancies, MS, and csu